日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

OTS167 blocks FLT3 translation and synergizes with FLT3 inhibitors in FLT3 mutant acute myeloid leukemia

OTS167 阻断 FLT3 翻译并与 FLT3 抑制剂在 FLT3 突变急性髓系白血病中产生协同作用

Bartholomew J Eisfelder, Caner Saygin, Joseph Wynne, Margaret W Colton, Mariafausta Fischietti, Elspeth M Beauchamp, Jason X Cheng, Olatoyosi Odenike, Gail Roboz, Houda Alachkar #, Wendy Stock #

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

Guadecitabine (SGI-110) 治疗中度或高度风险骨髓增生异常综合征患者:一项多中心、开放标签、随机、1/2 期临床试验的 2 期结果

Guillermo Garcia-Manero, Gail Roboz, Katherine Walsh, Hagop Kantarjian, Ellen Ritchie, Patricia Kropf, Casey O'Connell, Raoul Tibes, Scott Lunin, Todd Rosenblat, Karen Yee, Wendy Stock, Elizabeth Griffiths, Joseph Mace, Nikolai Podoltsev, Jesus Berdeja, Elias Jabbour, Jean-Pierre J Issa, Yong Hao, H

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

针对新诊断的急性髓性白血病老年人的主动口服治疗方案:法呢基转移酶抑制剂替比法尼布 (R115777,Zarnestra) 联合依托泊苷的临床前和 1 期试验

Judith E Karp, Karen Flatten, Eric J Feldman, Jacqueline M Greer, David A Loegering, Rebecca M Ricklis, Lawrence E Morris, Ellen Ritchie, B Douglas Smith, Valerie Ironside, Timothy Talbott, Gail Roboz, Son B Le, Xue Wei Meng, Paula A Schneider, Nga T Dai, Alex A Adjei, Steven D Gore, Mark J Levis, J